- Home
- CAPR vs MLP Comparison
CAPR vs MLP Comparison
Compare CAPR & MLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MLP
- Stock Information
- Founded
- CAPR 2005
- MLP 1909
- Country
- CAPR United States
- MLP United States
- Employees
- CAPR N/A
- MLP N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MLP Real Estate
- Sector
- CAPR Health Care
- MLP Finance
- Exchange
- CAPR Nasdaq
- MLP Nasdaq
- Market Cap
- CAPR 324.6M
- MLP 343.9M
- IPO Year
- CAPR N/A
- MLP 1972
- Fundamental
- Price
- CAPR $6.36
- MLP $18.60
- Analyst Decision
- CAPR Strong Buy
- MLP
- Analyst Count
- CAPR 8
- MLP 0
- Target Price
- CAPR $24.75
- MLP N/A
- AVG Volume (30 Days)
- CAPR 1.2M
- MLP 18.9K
- Earning Date
- CAPR 11-12-2025
- MLP 08-14-2025
- Dividend Yield
- CAPR N/A
- MLP N/A
- EPS Growth
- CAPR N/A
- MLP N/A
- EPS
- CAPR N/A
- MLP N/A
- Revenue
- CAPR $13,392,150.00
- MLP $16,843,000.00
- Revenue This Year
- CAPR N/A
- MLP N/A
- Revenue Next Year
- CAPR $6,061.53
- MLP N/A
- P/E Ratio
- CAPR N/A
- MLP N/A
- Revenue Growth
- CAPR N/A
- MLP 74.59
- 52 Week Low
- CAPR $4.05
- MLP $14.05
- 52 Week High
- CAPR $23.40
- MLP $25.78
- Technical
- Relative Strength Index (RSI)
- CAPR 42.32
- MLP 65.46
- Support Level
- CAPR $6.05
- MLP $16.72
- Resistance Level
- CAPR $6.62
- MLP $17.55
- Average True Range (ATR)
- CAPR 0.39
- MLP 0.62
- MACD
- CAPR 0.05
- MLP 0.17
- Stochastic Oscillator
- CAPR 47.89
- MLP 76.86
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.